Free Trial Information
BioCentury | Aug 13, 2007
Product Development

Faster followers in pain

...YM: Personalized dosing In 2005, YM Biosciences Inc. paid $3.7 million in stock to purchase Delex Therapeutics Inc....
Read More
BioCentury | May 9, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...are eligible for additional YM shares if certain milestones are met (see BioCentury, April 18). Delex Therapeutics Inc....
Read More
BioCentury | Apr 18, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...YM will pay Delex shareholders an additional C$4.8 million (US$3.9 million) in cash or stock. Delex Therapeutics Inc....
Read More
BioCentury | Oct 11, 2004
Clinical News

AeroLEF: Phase IIa data

...Phase IIa trial in 24 patients, 95% of patients safely self-titrated AeroLEF and achieved analgesia. Delex Therapeutics Inc....
Read More
BioCentury | Jun 14, 2004
Clinical News

AeroLEF: Phase IIa complete

...trial in 24 patients. The company said data are expected over the next few months. Delex Therapeutics Inc....
Read More
BioCentury | Mar 8, 2004
Clinical News

AeroLEF fentanyl: Phase II

...Delex began dosing in a Canadian Phase II trial of AeroLEF in 24 patients. Delex Therapeutics Inc....
Read More
BioCentury | Nov 3, 2003
Company News

Delex Therapeutics board of directors update

Delex Therapeutics Inc. , Mississauga, Ontario Business: Drug delivery Appointed: David Howard, chairman of Angiotech Pharmaceuticals Inc. WIR Staff...
Read More
Items per page:
1 - 7 of 7
BioCentury | Aug 13, 2007
Product Development

Faster followers in pain

...YM: Personalized dosing In 2005, YM Biosciences Inc. paid $3.7 million in stock to purchase Delex Therapeutics Inc....
Read More
BioCentury | May 9, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...are eligible for additional YM shares if certain milestones are met (see BioCentury, April 18). Delex Therapeutics Inc....
Read More
BioCentury | Apr 18, 2005
Company News

Delex Therapeutics, YM BioSciences deal

...YM will pay Delex shareholders an additional C$4.8 million (US$3.9 million) in cash or stock. Delex Therapeutics Inc....
Read More
BioCentury | Oct 11, 2004
Clinical News

AeroLEF: Phase IIa data

...Phase IIa trial in 24 patients, 95% of patients safely self-titrated AeroLEF and achieved analgesia. Delex Therapeutics Inc....
Read More
BioCentury | Jun 14, 2004
Clinical News

AeroLEF: Phase IIa complete

...trial in 24 patients. The company said data are expected over the next few months. Delex Therapeutics Inc....
Read More
BioCentury | Mar 8, 2004
Clinical News

AeroLEF fentanyl: Phase II

...Delex began dosing in a Canadian Phase II trial of AeroLEF in 24 patients. Delex Therapeutics Inc....
Read More
BioCentury | Nov 3, 2003
Company News

Delex Therapeutics board of directors update

Delex Therapeutics Inc. , Mississauga, Ontario Business: Drug delivery Appointed: David Howard, chairman of Angiotech Pharmaceuticals Inc. WIR Staff...
Read More
Items per page:
1 - 7 of 7